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Efficacy of Epinastine Hydrochloride
for Antigen-Provoked Nasal
Symptoms in Subjects with Orchard
Grass Pollinosis
Minoru Gotoh1, Kazuhiro Hashiguchi2 and Kimihiro Okubo1
ABSTRACT
Background: Among the gramineae species, orchard grass is a typical causative pollen that provokes sea-
sonal rhinitis. The purpose of this study was to examine the protective efficacy of epinastine hydrochloride for
signs and symptoms caused by repeated nasal provocation with discs containing orchard grass pollen.
Methods: A single-dose, placebo-controlled, double-blind, crossover clinical study was conducted in subjects
with orchard grass pollinosis. The pollen challenge was conducted with the use of provocation discs containing
orchard grass pollen.
Results: Epinastine hydrochloride suppressed nasal symptoms caused by nasal provocation tests using or-
chard grass pollen discs. Among the nasal symptoms, the number of sneezing was significantly inhibited 30
minutes and 60 minutes after the administration of epinastine hydrochloride, as compared with placebo. There
were no adverse reactions to the study drugs.
Conclusions: Our results suggest that nasal provocation tests with discs containing orchard grass pollen is a
useful method for evaluating the onset of action of antiallergic drugs. As compared with placebo, epinastine hy-
drochloride decreased early-phase sneezing and the total nasal symptom score after repeated nasal provoca-
tions with orchard grass pollen discs.
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INTRODUCTION
Japanese cedar pollinosis has become a nationwide
disease, affecting at least 30 million persons in Japan.
Increasing airborne concentrations of Japanese cedar
pollen throughout Japan is considered an important
reason for such a high prevalence of related aller-
gies.1-3 Besides cedar and cypress, pollen of other
trees, grass, and weeds can evoke various ocular, res-
piratory, and nasal allergic reactions.
However, in Japan few studies have focused on pol-
lens other than Japanese cedar pollen. The dispersal
season of Japanese cedar pollen is from late winter to
spring. Even after the season ends, many patients
continue to have symptoms of allergic rhinitis.1 Such
symptoms are attributed to allergies to other pollens.
Therefore, treatment-related decisions should include
an assessment of pollinosis caused by other pollens,
as well as Japanese cedar pollinosis.
In 1991 we previously reported the results of im-
munological studies in 1329 patients with nasal al-
lergy, including sensitization rates, onset rates, and
prevalence rates of pollinosis associated with eight
kinds of pollen. In that survey we reported that
among 792 patients, 24.1% tested positive for antibod-
ies specific to orchard grass pollen,4 which is consis-
tent with the findings of Practical Guideline for the
Management of Allergic Rhinitis in Japan (revised in
2009).1 Since the antigenicity of grass pollens is very
similar to that of other pollens, a definitive diagnosis
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Table　1　Medication and provocation schedule
Provocation
Provocation and treatment times 
(minutes)
-65 -60 0 30 60 180
Dummy disc 〇
Provocation-1 〇
Study drug medication 〇
Provocation-2 〇
Provocation-3 〇
Provocation-4 〇
of orchard grass pollinosis is more challenging than
that of Japanese cedar pollinosis. It is therefore diffi-
cult to pinpoint the season in which orchard grass
pollen is dispersed. The occurrence of subclinical
symptoms can also preclude the diagnosis of orchard
grass pollinosis. Although the prevalence of orchard
grass pollinosis remains unclear, the number of pa-
tients with this disease has apparently increased. As a
leading cause of allergy, grass pollens are thought to
come after cedar and cypress pollens. Patients with
allergic rhinitis have symptoms such as sneezing, na-
sal stuffiness, and nasal discharge, negatively affect-
ing their quality of life.
Identifying the causative pollen is important step in
the management of allergic rhinitis; treatment effec-
tive against the causative pollen is then required. An-
tiallergic agents are the mainstay of treatment for al-
lergic rhinitis. Our previous studies have shown that
among the approved antiallergic agents in Japan,
epinastine hydrochloride is highly effective for the
prevention and management of seasonal rhinitis in-
duced by Japanese cedar pollen.5 Since nasal allergic
reactions induced by orchard grass pollen are
thought to be provoked by the same mechanisms as
those induced by Japanese cedar pollen, we tested
the hypothesis that epinastine hydrochloride is also
effective for allergic rhinitis induced by orchard grass
pollen.
We conducted this clinical study to evaluate the in-
hibitory potency of epinastine hydrochloride for or-
chard grass pollen-provoked allergic rhinitis. We per-
formed nasal provocation tests using provocation
discs containing orchard grass pollen at a concentra-
tion of 120 (weightvolume). The provocation and
observation points were similar to those in our previ-
ous study in patients with Japanese cedar pollinosis.
The design and results have been reported else-
where.5
METHODS
SUBJECTS
The inclusion criteria required that the subject had a
CAP score of3 within the past 3 years and positive
results on nasal provocation tests6 with orchard grass
pollen at screening. All subjects provided written in-
formed consent in compliance with Good Clinical
Practice guidelines for clinical studies.
Volunteers were excluded as subjects if they had a
history of allergy or hypersensitivity to the ingredi-
ents of epinastine hydrochloride; received treatment
with any form of corticosteroids within 1 month be-
fore the date of screening; received medication poten-
tially affecting the results of the clinical study within 1
week before the date of screening (e.g., any form of
antihistamines, antiallergic agents, or vasoconstric-
tors); were expected to have a poor response to
provocation testing on the basis of the response to
previous laser therapy or hyposensitization therapy
for orchard grass pollinosis; or had underlying nasal
diseases potentially affecting the assessment of the
response to nasal provocation, such as acute or
chronic rhinitis, nasal polyps, hypertrophic rhinitis, a
deviated septum, or sinusitis. We also excluded
women who were pregnant, possibly pregnant, or
nursing infants, as well as volunteers who were
judged not to be eligible for enrollment by the investi-
gators. The enrolled subjects were examined 3 times:
at screening before the initiation of the study (Visit
0), Visit 1, and Visit 2. Visit 1 and Visit 2 were sepa-
rated by a 1-week interval.
This study was conducted between November and
December 2009 in accordance with the principles em-
bodied in the Declaration of Helsinki of 1995 (as re-
vised in Edinburgh 2000). The protocol was reviewed
and approved by an independent institutional review
board of Shinanozaka Clinic (Tokyo, Japan) before
study initiation and subject recruitment.
STUDY DESIGN
This was a single-dose, placebo-controlled, double-
blind, randomized, crossover study.
A total of 16 subjects with orchard grass pollinosis
who met the eligibility criteria were randomly as-
signed to receive either epinastine hydrochloride 20
mg or a matched placebo at Visit 1.
Before initiation of the provocation study, a dummy
disc (containing no pollen) was placed on the nasal
inferior turbinates of a subject for 5 minutes to con-
firm that it caused no provocative signs. Provocations
were conducted at 4 time points: 60 minutes before
administration of the study drug and 30, 60, and 180
minutes after administration. Nasal provocation discs
containing orchard grass pollen were prepared by
dipping a round piece of filter paper 3 mm in diame-
ter in a 1 : 20 (WV) extract of orchard grass pollen.
The paper was then lyophilized.
Orchard grass pollen discs were bilaterally placed
on the inferior turbinates of a subject. Sixty minutes
after the first provocation, the subject received either
a 20-mg tablet of epinastine hydrochloride or a
matched placebo. The provocation and treatment
schedule is shown in Table 1.
Nasal signs and symptoms were evaluated for 4
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Table　2　Nasal symptoms score
Score 4 3 2 1 0
Severity ++++ +++ ++ + -
Number of sneezing (times) ≥21 ≥11 to ≤20 ≥6 to ≤10 ≥1 to ≤5 none
Discharge volume (g) ≥2 ≥1.5 to <2 ≥1 to <1.5 ≥0.5 to <1 <0.5
Inferior nasal turbinate mucosal 
swelling -
middle
turbinate not
seen
intermediate
between
(3) and (1)
to center of
middle
turbinate
none
time periods: -60 to -55 minutes before treatment, and
30 to 35 minutes, 60 to 65 minutes, and 180 to 185
minutes after treatment. The following nasal symp-
toms were assessed: number of sneezing, presence
or absence of pruritus, and volume of nasal dis-
charge, which was measured by weighing the tissue
paper used by the subject. The swellingcolor of the
inferior turbinate as well as the quality and quantity
of nasal secretion in the inferior turbinate were as-
sessed by rhinoscopy.
The nasal mucosa was bilaterally examined and
either videotape-recorded or photographed. A vide-
otape recording was taken for 1-minute intervals
starting immediately after and 5 minutes after each
provocation. One week after Visit 1, 14 of the 16 sub-
jects were re-studied at Visit 2. Subjects were exam-
ined in the same manner as the previous visit, except
that they received the opposite treatment to that ad-
ministered at Visit 1.
STUDY DRUGS
Epinastine hydrochloride tablets (with fees paid) and
matched placebo tablets were provided by Nippon
Boehringer Ingelheim Co., Ltd., Tokyo, Japan. Or-
chard grass pollen was provided by Allergon AB
(with fees paid), Sweden. Test discs containing or-
chard grass pollen were kindly prepared and pro-
vided by Dr. Hiroshi Yasueda, Clinical Research Cen-
ter for Allergy and Rheumatology, National Hospital
Organization, Sagamihara National Hospital.
EVALUATIONS
The efficacy of epinastine hydrochloride against the
response to nasal provocation was evaluated on the
basis of the changes in nasal symptoms and other
variables, evaluated at the predetermined time points.
Four rhinoscopic examinations were conducted 5
minutes after each provocation. Swelling and color of
the inferior turbinate mucosa, watery discharge vol-
ume, and discharge properties were recorded. Table
2 shows the criteria for scoring nasal symptoms. The
total nasal symptom score in this study was based on
the number of sneezing, nasal discharge weight, and
inferior turbinate mucosal swelling (instead of nasal
obstruction) in accordance with Practical Guideline
for the Management of Allergic Rhinitis in Japan.1
The primary end point of this study was the change
in nasal symptoms. The secondary endpoint was the
physiological change in nasal findings. To evaluate
safety, investigators examined the subjects at Visit 1
and Visit 2. Physical, serum chemical, and 12-lead
electrocardiographic examinations were conducted at
screening and at the completion of the study.
STATISTICAL ANALYSIS
The number of sneezing and nasal discharge volume
(g) at the predetermined time points were expressed
as actual values. For the total nasal symptom score,
the number of sneezing, nasal discharge volume, and
swelling severity of the inferior turbinate mucosa
were scored as shown in Table 2. For statistical analy-
sis, changes in the number of sneezing, nasal dis-
charge volume, and total nasal symptom score after
treatment were compared with the respective values
at the first provocation (-60 minutes before treat-
ment) in each study arm. The Wilcoxon rank sum
test with the Bonferroni correction was used for sta-
tistical analysis. The proportion of subjects with pruri-
tus of the nasal mucosa was statistically analyzed us-
ing Fisher’s exact test with the Bonferroni correction.
In this study, p < 0.05 was considered to indicate sta-
tistical significance.
RESULTS
A total of 16 subjects (13 males and 3 females) aged
between 21 and 42 years (mean ± SD, 30.75 ± 7.48)
were enrolled. The baseline characteristics of sub-
jects are shown in Table 3. The results of single
provocation tests at screening are shown in Table 4.
Nasal symptoms (number of sneezing, nasal dis-
charge volume, nasal pruritus), nasal provocation test
scores, and local nasal findings (swelling and color
tone of the inferior nasal turbinate mucosa, watery
discharge volume, nasal discharge properties) are
presented. Fourteen of the 16 subjects completed the
study; two subjects withdrew at Visit 2 because of a
common cold, considered unrelated to the study drug
by the investigator. Data from 14 and 16 subjects
were thus included in efficacy and safety analyses, re-
spectively.
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Table　3　Baseline characteristics of subjects (n = 16)
Gender
male 13
female  3
Age (years)
≥21 to <30  8
≥30 to <40  5
≥40 to ≤42  3
mean ± SD 30.75 ± 7.48
Age at onset (years)
 ≥7 to <10  3
≥10 to <20  7
≥20 to <30  3
≥30 to <40  1
=40  1
unknown  1
mean ± SD 17.80 ± 9.45
Duration from the onset 
(years)
 ≥1 to <10  5
≥10 to <20  8
≥20 to ≤29  2
unknown  1
mean ± SD 12.80 ± 7.45
CAP (score)†
orchard grass  3.44 ± 0.63
ragweed  1.31 ± 1.08
Japanese cedar  3.88 ± 1.36
Japanese cypress  2.21 ± 1.19
mites  1.88 ± 1.31
house dust  2.00 ± 1.21
Co-existing disease
no 12
yes‡  4
History of prior allergy
no 16
yes  0
Prior therapy
no 16
yes  0
†Values represent means with standard deviation.
‡All co-existing diseases were seasonal allergic conjunctivitis.
Table　4　Results of single provocation tests at screening
(n = 16)
Number of sneezing (times)
none 0
≥1 to ≤5 10
 ≥6 to ≤10 6
≥11 to ≤20 0
≥21 0
min. 2
max. 10
mean ± SD 4.25 ± 2.98
Nasal discharge volume (g)
<0.5 1
≥0.5 to <1 1
≥1 to <1.5 3
≥1.5 to < 2 6
≥2 5
min.    0.38
max.    3.17
mean ± SD 1.71 ± 0.71
Nasal pruritus
no 0
yes 16
Nasal provocation test score
- 0
± 0
+ 3
++ 9
+++ 4
Inferior nasal turbinate mucosal 
swelling
- 2
+ 12
++ 2
+++ 0
Inferior nasal turbinate mucosal 
color tone
- 4
+ 8
++ 2
+++ 2
Watery discharge volume
- 0
+ 3
++ 5
+++ 8
Nasal discharge properties
- 0
+ 0
++ 0
+++ 16
NASAL SYMPTOMS
The change in the number of sneezing differed sig-
nificantly between epinastine hydrochloride and pla-
cebo at the early time points of 30 minutes and 60
minutes after treatment, but did not differ at 180 min-
utes (Wilcoxon rank sum test with Bonferroni correc-
tion: p = 0.0052, 0.0111 and 0.2502, respectively). The
nasal discharge volume decreased slightly, but not
significantly at the early time points after treatment
with epinastine hydrochloride (p = 0.2674, 0.8104 and
1.0000) as shown in Table 5. The change in the nasal
symptom score of the number of sneezing differed
significantly between epinastine hydrochloride and
placebo at the early time points of 30 minutes and 60
minutes after treatment (Wilcoxon rank sum test with
Bonferroni correction: P = 0.0092 and p = 0.0090) as
shown in Table 6. The total nasal symptom score also
decreased significantly 30 minutes after provocation
(p < 0.05) as shown in Figure 1. As for pruritus,
Fisher’s exact test with the Bonferroni correction in-
dicated a decreasing trend 180 minutes after treat-
ment with epinastine hydrochloride as compared
with placebo. However, there were no significant dif-
ferences between the two drug groups -60, 30, 60, or
180 minutes after administration (p = 1.0000, 1.0000,
1.0000, and 0.1843) as shown in Table 7.
NASAL EXAMINATION BY RHINOSCOPY
Swelling and color tone of the nasal mucosa were
Epinastine in Orchard Grass Pollinosis
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Table　5　Change in nasal signs and symptoms (n = 14)
Symptom Time points (minutes) Study drugs Mean SD SE
Quartiles
p value†
Min. 1st Median 3rd Max.
Number of 
sneezing 
(times)
 30
epinastine -4.9 5.3 1.4 -21 -5.0 -3.5 -3.0  0
0.0052
placebo  0.4 3.9 1.0  -4 -2.0 -1.0  2.0  8
 60
epinastine -6.0 4.5 1.2 -15 -9.0 -6.5 -2.0  0
0.0111
placebo  0.3 5.5 1.5 -11 -4.0  0.5  3.0 10
180
epinastine -4.3 7.0 1.9 -21 -7.0 -3.0  0.0  8
0.2502
placebo -0.5 3.9 1.0  -7 -4.0  0.0  2.0  5
Discharge 
volume (g)
 30
epinastine -0.871 1.449 0.387 -4.24 -1.780 -0.625  0.000  1.81
0.2674
placebo  0.256 1.476 0.394 -1.79 -0.660 -0.095  0.890  3.56
 60
epinastine -0.331 1.192 0.319 -2.73 -0.960 -0.390  0.160  1.90
0.8104
placebo  0.204 1.302 0.348 -1.80 -0.450 -0.020  1.070  2.48
180
epinastine -0.249 2.384 0.637 -4.20 -1.480 -0.220  0.420  5.95
1.0000
placebo -0.096 1.007 0.269 -1.14 -1.090 -0.390  1.060  1.27
†Wilcoxon rank sum test with Bonferroni correction.
Table　6　Change in nasal symptom score (n = 14)
Symptom Time points (minutes) Study drugs Mean SD SE
Quartiles
p value†
Min. 1st Median 3rd Max.
Swellings of 
inferior nasal 
turbinate
 30
epinastine -0.1 0.6 0.2 -1  0.0  0.0 0.0 1
0.3982
placebo  0.3 0.6 0.2 -1  0.0  0.0 1.0 1
 60
epinastine  0.6 1.3 0.4 -2  0.0  1.0 1.0 3
1.0000
placebo  0.7 0.8 0.2 -1  0.0  1.0 1.0 2
180
epinastine  0.4 0.9 0.2 -1  0.0  0.0 1.0 2
0.8556
placebo  0.7 0.8 0.2  0  0.0  0.5 1.0 2
Number of 
sneezing
 30
epinastine -1.0 1.1 0.3 -4 -1.0 -1.0 0.0 0
0.0092
placebo  0.1 0.8 0.2 -1  0.0  0.0 0.0 2
 60
epinastine -1.1 0.9 0.2 -2 -2.0 -1.0 0.0 0
0.0090
placebo  0.1 0.9 0.2 -1 -1.0  0.0 1.0 2
180
epinastine -0.9 1.3 0.3 -4 -2.0 -1.0 0.0 1
0.0824
placebo -0.1 0.5 0.1 -1  0.0  0.0 0.0 1
Discharge 
volume
 30
epinastine -0.857 1.351 0.361 -3.00 -2.000 -0.500 0.000 2.00
0.2116
placebo  0.071 1.542 0.412 -3.00  0.000  0.000 0.000 4.00
 60
epinastine -0.071 1.269 0.339 -2.00 -1.000  0.000 0.000 3.00
1.0000
placebo  0.000 1.468 0.392 -3.00  0.000  0.000 0.000 4.00
180
epinastine -0.429 1.399 0.374 -2.00 -2.000  0.000 1.000 2.00
1.0000
placebo -0.214 1.051 0.281 -2.00 -1.000  0.000 0.000 2.00
†Wilcoxon rank sum test with Bonferroni correction.
evaluated on rhinoscopy at each time point and were
classified into 4 severity grades (negative to +++).
The quantity and quality of nasal secretion were also
assessed at the same time points. There was no dif-
ference in the swelling or color tone of the nasal mu-
cosa or in the quantity and quality of nasal secretion
between the two groups.
VIDEOTAPE RECORDING ON ANTERIOR RHI-
NOSCOPY
Intranasal images recorded at the predetermined ob-
servation time points are shown in Figure 2. The im-
ages suggested that epinastine hydrochloride may
decrease nasal swelling after provocation as com-
Gotoh M et al.
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Fig.　1　Change in total nasal symptom score. A total nasal
symptom is composed of nasal sneezing score, nasal dis-
charge score, and severity of swelling in inferior turbinate 
mucosa. ●: epinastine hydrochloride, ▲: placebo, vertical 
bar on symbols: mean ± SD. * p < 0.05.
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Table　7　Proportion of subjects with pruritus (n = 14)
Time points
(minutes)
Study 
drugs
Number of
positive
Ratio
(%) p value
†
-60
epinastine 12  85.7
1.0000
placebo 14 100.0
30
epinastine 11  78.6
1.0000
placebo 13  92.9
60
epinastine 11  78.6
1.0000
placebo 11  78.6
180
epinastine  6  42.9
0.1843
placebo 12  85.7
†Fisher’s exact with Bonferroni correction.
pared with placebo.
SAFETY
Safety was assessed in all 16 subjects. None of the
subjects had any adverse reaction attributed to the
study drugs during any part of the study period.
DISCUSSION
Identifying the causative pollen is an important factor
in the management of seasonal allergic rhinitis, but
weeds and grasses share common antigenic features.
In particular, adequate studies of orchard grass pol-
len are lacking. Studies and analyses of allergens
have been carried out globally, whereas antigens that
cause pollinosis vary by region.1
Choosing an effective treatment is another impor-
tant factor in the management of seasonal rhinitis.
Nasal provocation tests are convenient tools for non-
invasively identifying causative pollen antigens in pa-
tients with allergic rhinitis. Provocation tests have
been widely used to identify allergens because they
can be performed throughout the year, regardless of
the pollen season. Once the nasal mucosa of a subject
is exposed to an antigen, a specific IgE is induced,
eliciting allergic symptoms. In patients with cedar
pollinosis, provocation tests with nasal discs contain-
ing Japanese cedar pollen for 6 consecutive days in a
pollen-free season reproduced nasal signs and symp-
toms similar to those occurring during the cedar pol-
len season.7 Recent studies have reported that the
use of a pollen-scattering chamber is an effective
means of evaluating antiallergic drugs and may cause
conditions similar to the actual pollen-dispersing sea-
son. This method can elicit symptoms of pollinosis by
a specified antigen that evokes the provocative re-
sponse for individual subjects, but cannot measure
the volume of the causative antigen adhering to the
nasal mucosa. Another limitation is that the number
of scattering systems that can be used in clinical trials
is limited.
Nasal provocation tests are useful for the diagnosis
of pollinosis, but it is difficult to assess the correlation
between the severity of pollinosis in patients during
the pollen season and disease severity as evaluated
on nasal provocation tests. On the other hand, be-
cause allergic rhinitis is a type I allergic reaction, its
signs and symptoms depend on the amount of anti-
gen and the responsiveness of the nasal mucosa to
the antigen, i.e., the specific hypersensitivity of the in-
dividual. We consider it feasible to assess this specific
hypersensitivity in individual subjects by means of na-
sal provocation tests designed to determine the
amount of antigen required to produce symptoms or
the severity of nasal symptoms developing in re-
sponse to a given amount of antigen. We previously
reported that antihistamines significantly inhibited
nasal reactions as compared with placebo on re-
peated nasal provocation tests using discs containing
a specific amount of Japanese cedar antigen.6 We
therefore considered it feasible to perform a placebo-
controlled study to evaluate nasal responsiveness to
orchard grass pollen. In addition, to ensure that the
response to antihistamine treatment on repeated na-
sal provocation tests was evaluated as reliably as pos-
sible, we recruited subjects who had an orchard
grass CAP score of +3 or higher as well as two or
more nasal symptoms (+ or higher) on a single nasal
provocation test using orchard grass antigen discs at
screening. We thereby confirmed that the amount of
orchard grass antigen in the discs used in this study
was above the threshold level in all subjects. Further-
more, the number of sneezing and the quantity of na-
sal discharge elicited by a single provocation with or-
chard grass pollen discs at screening were within
well-defined ranges. The number of sneezing ranged
from a minimum of 2 to a maximum of 10 (mean ±
SD, 4.25 ± 2.98). Ten subjects had from 1 to less than
5 sneezings. The quantity of nasal discharge ranged
from a minimum of 0.38 g to a maximum of 3.17 g
Epinastine in Orchard Grass Pollinosis
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Fig.　2　The appearance of nasal mucosa on rhinoscopy. The nasal mucosa was examined immediately after and 
5 minutes after provocations -60, 30, 60 and 180 minutes after treatment with the assigned study drug.
-60 minutes 30 minutes 60 minutes 180 minutes
Placebo
Epinastine
Start of
provocation
Start of
provocation
5 minutes
after each 
provocation
5 minutes
after each 
provocation 
(mean ± SD, 1.71 ± 0.71 g). Nasal discharge was 1.5
to <2.0 g in 6 subjects and 2.0 g to 3.17 g in 5 sub-
jects. To minimize the effects of individual differences
among the subjects, the changes in the number of
sneezing and the quantity of nasal discharge as com-
pared with 60 minutes before administration of the
study drug rather than the actual values were used to
assess the effects of drug treatment on these vari-
ables.
This was a pilot study performed in a small number
of subjects. We carried out provocation tests by ap-
plying nasal discs containing a fixed amount of pollen
to the nasal mucosa and thereby assessed nasal
symptoms and rhinoscopic findings. Repeated provo-
cation tests were performed within several hours dur-
ing the non-pollen-dispersal season. Because the
study simulated exposure to pollen many times per
day, we could only confirm that the amount of anti-
gen contained in the discs was above the threshold
limit.
This present investigation was also a pilot study of
discs containing orchard grass antigen. Our results
suggested that nasal provocation tests using these
discs might be useful for the evaluation of drugs.
However, establishment of the usefulness of nasal
provocation tests for drug evaluation would require
further studies examining correlations between the
amount of pollen exposure (amount of pollen con-
tained in orchard grass pollen discs) and nasal reac-
tivity. Differences in individual responsiveness at a
fixed amount of antigen should also be studied.
Moreover, validation of the usefulness of repeated na-
sal provocation tests for drug evaluations would also
require the establishment of antigen levels, including
the threshold value, associated with the onset of na-
sal symptoms, studies of antigen levels higher and
lower than the threshold level in individual patients,
and studies of provocation tests performed on con-
secutive days, simulating pollen dispersal. Since pre-
vious studies have reported that eosinophil activation
starts 6 hours after antigen induction8 and that the
number of eosinophils in nasal discharge increases
significantly 6 to 10 hours after antigen induction,9
studies should also be performed6 hours after anti-
gen exposure to assess potential effects of eosinophil
activation.
The onset of action of epinastine hydrochloride for
the suppression of histamine-induced wheal and flare
response has been evaluated previously.10 The skin
response was inhibited 30 minutes after the admini-
Gotoh M et al.
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stration of epinastine hydrochloride. In the present
study, antigen induction was initially performed 30
minutes after the administration of epinastine hydro-
chlorid and the subject was repeatedly exposed to the
study antigen. Our previous 5-hour repeated nasal
provocation tests using Japanese cedar pollen discs5
also confirmed that nasal symptoms are suppressed
30 minutes after treatment with epinastine hydrochlo-
rode. However, both of these studies first evaluated
drug effectiveness at the predetermined time point of
30 minutes after administration. It thus may be diffi-
cult to extrapolate these results and estimate the on-
set of effectiveness against actual nasal symptoms.
As for the duration of action against provoked nasal
symptoms, subjects were observed for up to 180 min-
utes after administration of epinastine hydrochloride
or placebo. Effective blood levels of epinastine hydro-
chloride for antigen-induced nasal symptoms remain
unclear, but the peak drug concentration (Tmax) is
reached in 1.9 ± 1.4 hours, and the half-life is 9.2 ± 1.7
hours, suggesting that the duration of action is sev-
eral hours. In our previous 5-hour, repeated nasal
provocation tests using Japanese cedar antigen
discs,5 the number of sneezing and the amount of na-
sal discharge in the placebo group peaked 60 minutes
after administration, tended to decrease at 180 min-
utes, and returned to a similar level to that after the
first provocation at 300 minutes. We therefore consid-
ered it appropriate to evaluate nasal reactions for up
to 3 hours in repeated nasal provocation tests.
In this clinical study, we expected that epinastine
hydrochloride would be effective for sneezing, nasal
discharge, and swelling of the nasal mucosa elicited
by orchard grass pollen. However, epinastine hydro-
chloride significantly suppressed sneezing for up to
60 minutes after administration as compared with pla-
cebo, but was not effective against nasal discharge, in
contrast to the results of our previous study using ce-
dar pollen antigen.5 This discrepancy was most likely
attributed to differences in responsiveness caused by
different amounts of provocation antigens. Okamoto
et al. performed 5 to 6 nasal provocation tests using
orchard grass antigen discs at 30-minute intervals.11
The protocol for that study caused allergic reactions
of the eyes and face, as well as nasal symptoms. In
contrast, allergic reactions other than nasal symp-
toms did not occur after repeated provocation tests in
any subject in either the epinastine hydrochloride
group or placebo group. These differences in respon-
siveness and symptoms are probably ascribed to the
antigen contents of the discs. Assay methods for the
principal antigens of orchard grass pollen, Dac g 1
and Dac g 5, have not been established in Japan. We
were therefore unable to assay the main antigens in
the discs used in this study. It is therefore difficult to
comment further on potential reasons for the afore-
mentioned differences in responsiveness and symp-
toms. Further studies are awaited.
Early onset of effectiveness for allergy is directly
link to an improved quality of life (QOL) in patients
with allergic rhinitis.12 To achieve a better QOL, iden-
tification of the specific causative antigen is strongly
recommended and may contribute to early treatment
or prophylaxis during the initial or subsequent phase
of allergic rhinitis.
In our previous study using Japanese cedar antigen
disc,5 a priming effect was seen for up to 60 minutes
after administration of the study drug in the placebo
group. However, we performed nasal provocation
tests once daily for 8 days, using house dust mite al-
lergen discs. There was no distinct increase in nasal
symptoms.13 In the present study, we performed 3-
hour repeated provocation tests using orchard grass
antigen discs in a non-pollen season. There was no in-
crease in sneezing or nasal discharge from after the
first provocation in the placebo group. Our results
therefore did not shed light on whether or not re-
peated nasal provocation tests using antigen discs are
associated with a priming effect. Factors such as the
type and amount of antigen used for provocation or
the time intervals or number of days of provocation
may thus interact in a complex fashion, leading to dif-
ferences in the activation of mast cells or eosinophils.
In this study, sneezing was inhibited by epinastine
hydrochloride in the early phase, and the effect lasted
for up to 60 minutes after administration. Differences
in inhibitory latency among studies are poorly under-
stood and require further investigations. Repeated na-
sal provocations may deplete histamine release from
mast cells in the nasal mucosa. Sneezing tends to
subside within a few hours. No response was ob-
served 180 minutes after drug administration. We
strongly believe that our interventional study will set
a milestone for detecting and treating patients with
orchard grass pollinosis. Further studies of orchard
grass pollinosis should be conducted with the use of
nasal provocation discs containing various concentra-
tions of antigen.
In conclusion, this interventional study suggested
that nasal provocation tests with discs containing or-
chard grass pollen are useful for evaluating the onset
of action of antiallergic drugs. Epinastine hydrochlo-
ride inhibited nasal symptoms as compared with pla-
cebo. In particular, early-phase sneezing and total na-
sal symptom score after repeated nasal provocations
by orchard grass pollen were significantly decreased
by epinastine hydrochloride.
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